- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05979363
Un estudio de bortezomib, lenalidomida y dexametasona (VRd) seguido de terapia CAR-T con BCMA en pacientes con leucemia primaria de células plasmáticas no elegibles para trasplante (CAREMM-002)
Safety and Efficiency of VRd-based Regimen Combining BCMA CAR-T for Transplant-ineligible Patients With Primary Plasma Cell Leukemia: a Prospective, Single-arm, Single-center, Phase II Study.
This is a single-arm, open-label study to evaluate the efficacy and safety of VRD-based regimen combined with BCMA CAR-T in transplant-ineligible patients with primary plasma cell leukemia
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The study is a prospective, single-arm, single-centre, phase II study designed to evaluate the efficacy and safety of treatment with VRD-based regimen combined with BCMA CAR-T in transplant-ineligible patients with primary plasma cell leukemia. Patients received 3-4 courses of induction therapy with VRD-based regimen followed by infusion of BCMA CAR-T cells. Patients then received 2-3 courses of consolidation therapy, followed by maintenance therapy.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Gang An, PhD&MD
- Número de teléfono: 86-022-23909171
- Correo electrónico: angang@ihcams.ac.cn
Ubicaciones de estudio
-
-
-
Tianjin, Porcelana
- Reclutamiento
- Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
-
Contacto:
- Gang An, PhD&MD
- Número de teléfono: 008613502181109
- Correo electrónico: angang@ihcams.ac.cn
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age ≥ 18 years and ≤ 75 years.
- Participants with documented primary plasma cell leukemia according to IMWG diagnostic criteria (circulating plasma cells ≥5%, determined by morphology on peripheral blood smear; or absolute value of peripheral blood tumorigenic plasma cells exceeds 2×10^9/L).
- Measurable disease, at screening as defined by any of the following: Serum monoclonal paraprotein (M-protein) level ≥1.0 g/dL or urine M-protein level ≥200 mg/24 hours; or Light chain MM without measurable disease in serum or urine: serum Ig free-light chain (FLC) ≥10 mg/dL and abnormal serum Ig kappa lambda FLC ratio.
- Not considered for high-dose chemotherapy with Autologous Stem Cell Transplant (ASCT) due to: Ineligible due to advanced age (≥65); or Ineligible evaluated by researchers; or Eastern Cooperative Oncology Group Performance Status grade of 3 or 4; or Repeated hematopoietic stem cell mobilization failure; or Deferral of high-dose chemotherapy with ASCT as initial treatment.
- Bone marrow sample is confirmed as BCMA-positive by flow cytometry or pathological examination.
- All screening blood biochemistry: tests should be performed according to the protocol and within 14 days before enrollment. Screening laboratory values must meet the following criteria: a.TBIL<2 x upper limit of normal (ULN) (<3 x ULN in patients with Gilbert's syndrome); b.AST and ALT <3 x ULN.; c. Creatinine clearance ≥ 30mL/min (calculated using Cockroft-Gault formula).
- Routine blood tests (performed within 7 days, no RBC transfusion, no G-CSF/GM-CSF/platelet agonists, no drug correction within 14 days before screening, no PLT transfusion within 7 days) : WBC ≥ 1.5 x 109/L, ANC ≥ 1.0 x 109/L, Hb ≥ 70 g/L PLT ≥ 75 x 109/L (if BMPC < 50%) or PLT ≥ 50 x 109/L (if BMPC ≥ 50%).
- Patients must be able to take prophylactic anticoagulant therapy as recommended by the study.
- The woman is not breastfeeding, is not pregnant and agrees not to be pregnant during the study period and for the following 12 months. Male patients agreed that their spouse would not become pregnant during the study period and for 12 months thereafter.
Exclusion Criteria:
- Documented active amyloidosis.
- Documented with central nervous system (CNS) invasion.
- Prior exposure to any BCMA-targeted therapy or CAR-T therapy.
- Patients with peripheral neuropathy greater than grade 2 or peripheral neuropathy greater than grade 2 with pain at baseline, regardless of whether they were currently receiving medical therapy.
- Known intolerance, hypersensitivity, or contraindication to glucocorticoids, bortezomib, lenalidomide, and BCMA-CART cellular products.
- Seropositive for human immunodeficiency virus (HIV)
- Hepatitis B infection
- Hepatitis C infection
- Life expectancy of <6 months
- Women who are pregnant or breastfeeding
- Any active gastrointestinal dysfunction that affects the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that may affect the absorption of the studied treatment medication
- Subjects had major surgery within 2 weeks before randomization (for example, general anesthesia), or is not fully recovered from the surgery, or surgery is arranged during study period.
- Received live attenuated vaccine within 4 weeks prior to study treatment.
- According to the researcher's judgment, any condition including but not limited to serious mental illness, medical illness, or other symptoms/conditions that may affect study treatment, compliance, or the capability of providing informed consent.
- Necessary medication or supportive therapy is contraindicated with study treatment.
- Any diseases or complications that may interfere with the study.
- Patients are not willing to or cannot comply with study scheme.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: VRD-based Regimen Combined With BCMA CART
VRD:Bortezomib, Lenalidomide and Dexamethasone Bortezomib SC 1.3mg/sqm on day 1,8,15,22, Lenalidomide oral 25 mg on day 1-21, and Dexamethasone 40mg on day 1,8,15,22 in a 28-day cycle. BCMA CAR-T products: YK-BB-002: Target dose of 3.0 × 10⁶ CAR-positive T cells/kg; Equecabtagene autoleucel: Planned dose of 1.0 × 10⁶ CAR-positive T cells/kg. Participants will receive VRD-based induction, BCMA CAR-T infusion, consolidation, and maintenance. |
Patients receive a single intravenous infusion of one of two BCMA-directed autologous CAR T-cell products: YK-BB-002: Target dose of 3.0 × 10⁶ CAR-positive T cells/kg; Equecabtagene autoleucel: Planned dose of 1.0 × 10⁶ CAR-positive T cells/kg. Bortezomib, Lenalidomide and Dexamethasone |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Safety and Tolerability
Periodo de tiempo: Up to 2 year
|
The incidence of treatment-emergent adverse events (TEAEs) |
Up to 2 year
|
|
MRD-negative rate
Periodo de tiempo: within 1 week after consolidation treatment
|
achieving MRD-negative, as determined by NGF after consolidation treatment |
within 1 week after consolidation treatment
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Complete response rate (CRR)
Periodo de tiempo: within 1 week after induction therapy, 1 month after the CAR-T cell transfusion, within 1 week after consolidation therapy
|
CR or better is defined as percentage of participants who achieve a CR response or Stringent Complete Response (sCR) response accoording to the IMWG criteria |
within 1 week after induction therapy, 1 month after the CAR-T cell transfusion, within 1 week after consolidation therapy
|
|
Progression free survival (PFS)
Periodo de tiempo: Up to 2 year
|
Progression free survival is defined as the time from the date of enrollment to the date of first documented PD, as defined in the IMWG criteria, or death due to any cause, whichever occurs first |
Up to 2 year
|
|
Overall Survival (OS)
Periodo de tiempo: Up to 5 year
|
Overall survival is measured from the date of enrollment to the date of the participant's death. |
Up to 5 year
|
|
Duration of Remission(DOR)
Periodo de tiempo: Up to 2 year
|
Duration of response is defined as the time from the first documented partial response (PR) or better to disease progression or death from any cause, whichever occurs first. |
Up to 2 year
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The duration of CART cell in vivo
Periodo de tiempo: Up to 1 year
|
The copies of BCMA-CART DNA in peripheral blood with qPCR method |
Up to 1 year
|
|
Change from Baseline in Physical status assessed by International Myeloma Working Group Comprehensive Geriatric Assessment (IMWG-CGA) scores
Periodo de tiempo: Baseline up to 5 years
|
The IMWG-CGA was calculated by combining age, activities of daily living (ADL), instrumental ADL (IADL), and Charlson Comorbidity Index (CCI), which ranges from 0 to 5 with higher scores indicating worse physical condition and greater weakness. |
Baseline up to 5 years
|
|
Change from Baseline in Physical status assessed by activities of daily living (ADL) scores
Periodo de tiempo: Baseline up to 5 years
|
The ADL includes 4 items (transfer, bed mobility, toileting, and eating), which range from 0 to 6 scores. A higher score represents worse physical condition and greater weakness. |
Baseline up to 5 years
|
|
Change from Baseline in Physical status assessed by instrumental activities of daily living (IADL) scores
Periodo de tiempo: Baseline up to 5 years
|
The IADL includes 5 items (cooking, cleaning, transportation, laundry, and managing finances), which range from 0 to 8 scores. A higher score represents worse physical condition and greater weakness. |
Baseline up to 5 years
|
|
Change from Baseline in Physical status assessed by Charlson Comorbidity Index (CCI)
Periodo de tiempo: Baseline up to 5 years
|
The CCI estimates the number and the severity of comorbidities, including nineteen diseases with a score varying from 1 to 6 for each of them in accordance to their severity. The score can range from 0 to 37. A higher score represents more severe comorbidities. |
Baseline up to 5 years
|
Colaboradores e Investigadores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- IIT2023034
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .